The Pituitary Tumors and Their Tumor-Specific Microenvironment.
Pituitary adenoma
Pituitary metastasis
Pituitary tumor
Tumor infiltrating lymphocytes
Tumor microenvironment
Tumor-associated macrophages
Tumor-to-tumor metastasis
Journal
Advances in experimental medicine and biology
ISSN: 0065-2598
Titre abrégé: Adv Exp Med Biol
Pays: United States
ID NLM: 0121103
Informations de publication
Date de publication:
2020
2020
Historique:
entrez:
29
6
2021
pubmed:
1
1
2020
medline:
2
7
2021
Statut:
ppublish
Résumé
Pituitary tumors develop within a macroenvironment and microenvironment that favor their overall survival. Given the pituitary gland's unique anatomic, histological, and physiological properties, the role of the TME in the pituitary tumors is central. This chapter summarizes the body of literature investigating the role of each component of the TME in relation to tumors of the pituitary and its intimate association with tumorigenesis, maintenance, and progression.
Identifiants
pubmed: 34185289
doi: 10.1007/978-3-030-59038-3_7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
117-135Références
Asa SL (2000) Pituitary Histopathology in Man: Normal and Abnormal. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, Dungan K, Grossman A, et al. (ed) Endotext. South Dartmouth (MA)
Joyce JA, Fearon DT (2015) T cell exclusion, immune privilege, and the tumor microenvironment. Science 348(6230):74–80
pubmed: 25838376
doi: 10.1126/science.aaa6204
pmcid: 25838376
Spill F, Reynolds DS, Kamm RD, Zaman MH (2016) Impact of the physical microenvironment on tumor progression and metastasis. Curr Opin Biotechnol 40:41–48
pubmed: 26938687
pmcid: 4975620
doi: 10.1016/j.copbio.2016.02.007
Hinshaw DC, Shevde LA (2019) The tumor microenvironment innately modulates Cancer progression. Cancer Res 79(18):4557–4566
pubmed: 31350295
pmcid: 6744958
doi: 10.1158/0008-5472.CAN-18-3962
Sato M, Tamura R, Tamura H, Mase T, Kosugi K, Morimoto Y et al (2019) Analysis of tumor angiogenesis and immune microenvironment in non-functional pituitary endocrine tumors. J Clin Med 8(5)
Sav A, Rotondo F, Syro LV, Scheithauer BW, Kovacs K (2012) Biomarkers of pituitary neoplasms. Anticancer Res 32(11):4639–4654
pubmed: 23155226
pmcid: 23155226
Brat DJ (2010) Normal brain histopathology. practical surgical neuropathology: a diagnostic approach. Elsevier, Philadelphia, p 26
Beatriz M LS, Pernicone PJ, Scheithauer BW, Horvath E, Kovacs K. Pituitary and sellar region. In: SE M, editor. Histology for pathologists. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2012. p. 343–372
Levy A, Lightman SL (1993) The pathogenesis of pituitary adenomas. Clin Endocrinol 38(6):559–570
doi: 10.1111/j.1365-2265.1993.tb02136.x
Scheithauer BW, Kovacs K, Horvath E, Silva AI, Lloyd RV (2010) Pathology of the pituitary and sellar region. In: Perry A, Brat DJ (eds) Practical surgical neuropathology: a diagnostic approach. Elsevier, Philadelphia, pp 371–416
doi: 10.1016/B978-0-443-06982-6.00018-3
Ashkenazi R, Gentry SN, Jackson TL (2008) Pathways to tumorigenesis--modeling mutation acquisition in stem cells and their progeny. Neoplasia 10(11):1170–1182
pubmed: 18953426
pmcid: 2570593
doi: 10.1593/neo.08572
Cao Y (2017) Tumorigenesis as a process of gradual loss of original cell identity and gain of properties of neural precursor/progenitor cells. Cell Biosci 7:61
pubmed: 29177029
pmcid: 5693707
doi: 10.1186/s13578-017-0188-9
Pepe S, Korbonits M, Iacovazzo D (2019) Germline and mosaic mutations causing pituitary tumours: genetic and molecular aspects. J Endocrinol 240(2):R21–R45
pubmed: 30530903
doi: 10.1530/JOE-18-0446
Levy A (2008) Molecular and trophic mechanisms of tumorigenesis. Endocrinol Metab Clin N Am 37(1):23–50. vii
doi: 10.1016/j.ecl.2007.10.009
Wang AR, Gill JR (2016) The pituitary gland: an infrequent but multifaceted contributor to death. Acad Forensic Pathol 6(2):206–216
pubmed: 31239893
pmcid: 6507013
doi: 10.23907/2016.023
Freda PU, Wardlaw SL, Post KD (1996) Unusual causes of sellar/parasellar masses in a large transsphenoidal surgical series. J Clin Endocrinol Metab 81(10):3455–3459
pubmed: 8855784
Valassi E, Biller BM, Klibanski A, Swearingen B (2010) Clinical features of nonpituitary sellar lesions in a large surgical series. Clin Endocrinol 73(6):798–807
doi: 10.1111/j.1365-2265.2010.03881.x
Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML et al (2004) The prevalence of pituitary adenomas: a systematic review. Cancer 101(3):613–619
pubmed: 15274075
doi: 10.1002/cncr.20412
Tampourlou M, Fountas A, Ntali G, Karavitaki N (2018) Mortality in patients with non-functioning pituitary adenoma. Pituitary 21(2):203–207
pubmed: 29344906
pmcid: 5849651
doi: 10.1007/s11102-018-0863-9
Mete O, Lopes MB (2017) Overview of the 2017 WHO classification of pituitary tumors. Endocr Pathol 28(3):228–243
pubmed: 28766057
doi: 10.1007/s12022-017-9498-z
Dworakowska D, Grossman AB (2009) The pathophysiology of pituitary adenomas. Best Pract Res Clin Endocrinol Metab 23(5):525–541
pubmed: 19945021
doi: 10.1016/j.beem.2009.05.004
Mayson SE, Snyder PJ (2015) Silent pituitary adenomas. Endocrinol Metab Clin N Am 44(1):79–87
doi: 10.1016/j.ecl.2014.11.001
Florio T (2011) Adult pituitary stem cells: from pituitary plasticity to adenoma development. Neuroendocrinology 94(4):265–277
pubmed: 22116388
doi: 10.1159/000330857
Dinicola S, D'Anselmi F, Pasqualato A, Proietti S, Lisi E, Cucina A et al (2011) A systems biology approach to cancer: fractals, attractors, and nonlinear dynamics. OMICS 15(3):93–104
pubmed: 21319994
doi: 10.1089/omi.2010.0091
Chen P, Zhao D, Li J, Liang X, Li J, Chang A et al (2019) Symbiotic macrophage-glioma cell interactions reveal synthetic lethality in PTEN-null glioma. Cancer Cell 35(6):868–884. e6
pubmed: 31185211
pmcid: 6561349
doi: 10.1016/j.ccell.2019.05.003
Zhenye L, Chuzhong L, Youtu W, Xiaolei L, Lei C, Lichuan H et al (2014) The expression of TGF-beta1, Smad3, phospho-Smad3 and Smad7 is correlated with the development and invasion of nonfunctioning pituitary adenomas. J Transl Med 12:71
pubmed: 24636138
pmcid: 3995298
doi: 10.1186/1479-5876-12-71
Zheng Q, Han L, Dong Y, Tian J, Huang W, Liu Z et al (2014) JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma. Neuro-Oncology 16(9):1229–1243
pubmed: 24861878
pmcid: 4136898
doi: 10.1093/neuonc/nou046
Feng J, Yu SY, Li CZ, Li ZY, Zhang YZ (2016) Integrative proteomics and transcriptomics revealed that activation of the IL-6R/JAK2/STAT3/MMP9 signaling pathway is correlated with invasion of pituitary null cell adenomas. Mol Cell Endocrinol 436:195–203
pubmed: 27465831
doi: 10.1016/j.mce.2016.07.025
Lin Y, Jiang X, Shen Y, Li M, Ma H, Xing M et al (2009) Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors. Endocr Relat Cancer 16(1):301–310
pubmed: 18852163
doi: 10.1677/ERC-08-0167
Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M et al (2007) IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 117(12):3988–4002
pubmed: 18060036
pmcid: 2096439
doi: 10.1172/JCI32533
Liu F, Zhang T, Zou S, Jiang B, Hua D (2015) B7H3 promotes cell migration and invasion through the Jak2/Stat3/MMP9 signaling pathway in colorectal cancer. Mol Med Rep 12(4):5455–5460
pubmed: 26151358
doi: 10.3892/mmr.2015.4050
pmcid: 26151358
Kowshik J, Baba AB, Giri H, Deepak Reddy G, Dixit M, Nagini S (2014) Astaxanthin inhibits JAK/STAT-3 signaling to abrogate cell proliferation, invasion and angiogenesis in a hamster model of oral cancer. PLoS One 9(10):e109114
pubmed: 25296162
pmcid: 4189964
doi: 10.1371/journal.pone.0109114
Rubinfeld H, Shimon I (2012) PI3K/Akt/mTOR and Raf/MEK/ERK signaling pathways perturbations in non-functioning pituitary adenomas. Endocrine 42(2):285–291
pubmed: 22552912
doi: 10.1007/s12020-012-9682-3
pmcid: 22552912
Scully S, Francescone R, Faibish M, Bentley B, Taylor SL, Oh D et al (2012) Transdifferentiation of glioblastoma stem-like cells into mural cells drives vasculogenic mimicry in glioblastomas. J Neurosci 32(37):12950–12960
pubmed: 22973019
pmcid: 3461581
doi: 10.1523/JNEUROSCI.2017-12.2012
Di Michele J, Rotondo F, Kovacs K, Syro LV, Yousef GM, Cusimano MD et al (2017) Vasculogenic mimicry in clinically non-functioning pituitary adenomas: a histologic study. Pathol Oncol Res 23(4):803–809
pubmed: 28084580
doi: 10.1007/s12253-017-0196-4
pmcid: 28084580
Fernandez-Cortes M, Delgado-Bellido D, Oliver FJ (2019) Vasculogenic mimicry: become an endothelial cell “but not so much”. Front Oncol 9:803
pubmed: 31508365
pmcid: 6714586
doi: 10.3389/fonc.2019.00803
Cao Z, Bao M, Miele L, Sarkar FH, Wang Z, Zhou Q (2013) Tumour vasculogenic mimicry is associated with poor prognosis of human cancer patients: a systemic review and meta-analysis. Eur J Cancer 49(18):3914–3923
pubmed: 23992642
doi: 10.1016/j.ejca.2013.07.148
pmcid: 23992642
Birbrair A, Zhang T, Wang ZM, Messi ML, Olson JD, Mintz A et al (2014) Type-2 pericytes participate in normal and tumoral angiogenesis. Am J Physiol Cell Physiol 307(1):C25–C38
pubmed: 24788248
pmcid: 4080181
doi: 10.1152/ajpcell.00084.2014
Pieterse Z, Sinha D, Kaur P (2019) Pericytes in metastasis. Adv Exp Med Biol 1147:125–135
pubmed: 31147875
doi: 10.1007/978-3-030-16908-4_5
pmcid: 31147875
Sattiraju A, Mintz A (2019) Pericytes in glioblastomas: multifaceted role within tumor microenvironments and potential for therapeutic interventions. Adv Exp Med Biol 1147:65–91
pubmed: 31147872
pmcid: 7322693
doi: 10.1007/978-3-030-16908-4_2
Di Ieva A, Weckman A, Di Michele J, Rotondo F, Grizzi F, Kovacs K et al (2013) Microvascular morphometrics of the hypophysis and pituitary tumors: from bench to operating theatre. Microvasc Res 89:7–14
pubmed: 23651686
doi: 10.1016/j.mvr.2013.04.009
pmcid: 23651686
Miao Y, Zong M, Jiang T, Yuan X, Guan S, Wang Y et al (2016) A comparative analysis of ESM-1 and vascular endothelial cell marker (CD34/CD105) expression on pituitary adenoma invasion. Pituitary 19(2):194–201
pubmed: 26809958
pmcid: 4799238
doi: 10.1007/s11102-015-0698-6
Cosio G, Jeziorski MC, Lopez-Barrera F, De La Escalera GM, Clapp C (2003) Hypoxia inhibits expression of prolactin and secretion of cathepsin-D by the GH4C1 pituitary adenoma cell line. Lab Investig 83(11):1627–1636
pubmed: 14615416
doi: 10.1097/01.LAB.0000098429.59348.36
pmcid: 14615416
Struman I, Bentzien F, Lee H, Mainfroid V, D'Angelo G, Goffin V et al (1999) Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis. Proc Natl Acad Sci U S A 96(4):1246–1251
pubmed: 9990009
pmcid: 15448
doi: 10.1073/pnas.96.4.1246
Yang Q, Li X (2019) Molecular network basis of invasive pituitary adenoma: a review. Front Endocrinol (Lausanne) 10:7
doi: 10.3389/fendo.2019.00007
Kawamoto H, Uozumi T, Kawamoto K, Arita K, Yano T, Hirohata T (1996) Type IV collagenase activity and cavernous sinus invasion in human pituitary adenomas. Acta Neurochir 138(4):390–395
pubmed: 8738388
doi: 10.1007/BF01420300
pmcid: 8738388
Liu W, Matsumoto Y, Okada M, Miyake K, Kunishio K, Kawai N et al (2005) Matrix metalloproteinase 2 and 9 expression correlated with cavernous sinus invasion of pituitary adenomas. J Med Investig 52(3–4):151–158
doi: 10.2152/jmi.52.151
Hui P, Xu X, Xu L, Hui G, Wu S, Lan Q (2015) Expression of MMP14 in invasive pituitary adenomas: relationship to invasion and angiogenesis. Int J Clin Exp Pathol 8(4):3556–3567
pubmed: 26097538
pmcid: 4466925
Qu X, Yang W, Jiang M, Han T, Han L, Qu Y et al (2010) CD147 expression in pituitary adenomas and its significance for clinical outcome. Hum Pathol 41(8):1165–1171
pubmed: 20381119
doi: 10.1016/j.humpath.2009.10.023
pmcid: 20381119
Beaulieu E, Kachra Z, Mousseau N, Delbecchi L, Hardy J, Beliveau R (1999) Matrix metalloproteinases and their inhibitors in human pituitary tumors. Neurosurgery 45(6):1432–1440. discussion 40-1
pubmed: 10598711
doi: 10.1097/00006123-199912000-00033
Yoshida D, Nomura R, Teramoto A (2008) Regulation of cell invasion and signalling pathways in the pituitary adenoma cell line, HP-75, by reversion-inducing cysteine-rich protein with kazal motifs (RECK). J Neuro-Oncol 89(2):141–150
doi: 10.1007/s11060-008-9606-5
Whitelock JM, Murdoch AD, Iozzo RV, Underwood PA (1996) The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem 271(17):10079–10086
pubmed: 8626565
doi: 10.1074/jbc.271.17.10079
Recouvreux MV, Camilletti MA, Rifkin DB, Diaz-Torga G (2016) The pituitary TGFbeta1 system as a novel target for the treatment of resistant prolactinomas. J Endocrinol 228(3):R73–R83
pubmed: 26698564
doi: 10.1530/JOE-15-0451
Qiu L, He D, Fan X, Li Z, Liao C, Zhu Y et al (2011) The expression of interleukin (IL)-17 and IL-17 receptor and MMP-9 in human pituitary adenomas. Pituitary 14(3):266–275
pubmed: 21279695
doi: 10.1007/s11102-011-0292-5
Wang J, Zhang Z, Li R, Mao F, Sun W, Chen J et al (2018) ADAM12 induces EMT and promotes cell migration, invasion and proliferation in pituitary adenomas via EGFR/ERK signaling pathway. Biomed Pharmacother 97:1066–1077
pubmed: 29136943
doi: 10.1016/j.biopha.2017.11.034
Liu KW, Pajtler KW, Worst BC, Pfister SM, Wechsler-Reya RJ (2017) Molecular mechanisms and therapeutic targets in pediatric brain tumors. Sci Signal 10(470)
Mucha SA, Melen-Mucha G, Godlewski A, Stepien H (2007) Inhibition of estrogen-induced pituitary tumor growth and angiogenesis in Fischer 344 rats by the matrix metalloproteinase inhibitor batimastat. Virchows Arch 450(3):335–341
pubmed: 17235567
doi: 10.1007/s00428-006-0351-x
Gross RL, Steel CM, Levin AG, Singh S, Brubaker G (1975) In vitro immunological studies on east african cancer patients. III. Spontaneous rosette formation by cells from Burkitt lymphoma biopsies. Int J Cancer 15(1):139–143
pubmed: 1079203
doi: 10.1002/ijc.2910150116
David M, Shohat B, Hazaz B, Feuerman EJ, Joshua H (1980) Identification of T & B lymphocytes on skin sections from patients with lymphoproliferative disorders of the skin. J Invest Dermatol 75(6):491–494
pubmed: 7003028
doi: 10.1111/1523-1747.ep12524301
Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH et al (2018) The immune landscape of Cancer. Immunity 48(4):812–830. e14
pubmed: 5982584
pmcid: 5982584
doi: 10.1016/j.immuni.2018.03.023
Lu JQ, Adam B, Jack AS, Lam A, Broad RW, Chik CL (2015) Immune cell infiltrates in pituitary adenomas: more macrophages in larger adenomas and more T cells in growth hormone adenomas. Endocr Pathol 26(3):263–272
pubmed: 26187094
doi: 10.1007/s12022-015-9383-6
Barry S, Carlsen E, Marques P, Stiles CE, Gadaleta E, Berney DM, et al (2019) Tumor microenvironment defines the invasive phenotype of AIP-mutation-positive pituitary tumors. Oncogene
Lupi I, Manetti L, Caturegli P, Menicagli M, Cosottini M, Iannelli A et al (2010) Tumor infiltrating lymphocytes but not serum pituitary antibodies are associated with poor clinical outcome after surgery in patients with pituitary adenoma. J Clin Endocrinol Metab 95(1):289–296
pubmed: 19875479
doi: 10.1210/jc.2009-1583
Brilli L, Danielli R, Ciuoli C, Calabro L, Di Giacomo AM, Cerase A et al (2017) Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab. Endocrine 58(3):535–541
pubmed: 28401443
doi: 10.1007/s12020-017-1289-2
Daly AF, Jaffrain-Rea ML, Ciccarelli A, Valdes-Socin H, Rohmer V, Tamburrano G et al (2006) Clinical characterization of familial isolated pituitary adenomas. J Clin Endocrinol Metab 91(9):3316–3323
pubmed: 16787992
doi: 10.1210/jc.2005-2671
Beckers A, Aaltonen LA, Daly AF, Karhu A (2013) Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocr Rev 34(2):239–277
pubmed: 23371967
pmcid: 3610678
doi: 10.1210/er.2012-1013
Daly AF, Vanbellinghen JF, Beckers A (2007) Characteristics of familial isolated pituitary adenomas. Expert Rev Endocrinol Metab 2(6):725–733
pubmed: 30290472
doi: 10.1586/17446651.2.6.725
Leontiou CA, Gueorguiev M, van der Spuy J, Quinton R, Lolli F, Hassan S et al (2008) The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab 93(6):2390–2401
pubmed: 18381572
doi: 10.1210/jc.2007-2611
Hernandez-Ramirez LC, Martucci F, Morgan RM, Trivellin G, Tilley D, Ramos-Guajardo N et al (2016) Rapid proteasomal degradation of mutant proteins is the primary mechanism leading to tumorigenesis in patients with missense AIP mutations. J Clin Endocrinol Metab 101(8):3144–3154
pubmed: 27253664
pmcid: 4971335
doi: 10.1210/jc.2016-1307
Salvatori R, Radian S, Diekmann Y, Iacovazzo D, David A, Gabrovska P et al (2017) In-frame seven amino-acid duplication in AIP arose over the last 3000 years, disrupts protein interaction and stability and is associated with gigantism. Eur J Endocrinol 177(3):257–266
pubmed: 28634279
pmcid: 5510572
doi: 10.1530/EJE-17-0293
Trivellin G, Daly AF, Faucz FR, Yuan B, Rostomyan L, Larco DO et al (2014) Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. N Engl J Med 371(25):2363–2374
pubmed: 25470569
pmcid: 4291174
doi: 10.1056/NEJMoa1408028
Zhang X, Sun H, Danila DC, Johnson SR, Zhou Y, Swearingen B et al (2002) Loss of expression of GADD45 gamma, a growth inhibitory gene, in human pituitary adenomas: implications for tumorigenesis. J Clin Endocrinol Metab 87(3):1262–1267
pubmed: 11889197
pmcid: 11889197
Zhang X, Zhou Y, Mehta KR, Danila DC, Scolavino S, Johnson SR et al (2003) A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. J Clin Endocrinol Metab 88(11):5119–5126
pubmed: 14602737
doi: 10.1210/jc.2003-030222
pmcid: 14602737
Duchen LW (1966) Metastatic carcinoma in the pituitary gland and hypothalamus. J Pathol Bacteriol 91(2):347–355
pubmed: 5918618
doi: 10.1002/path.1700910208
pmcid: 5918618
Saeger W, Ludecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S (2007) Pathohistological classification of pituitary tumors: 10 years of experience with the German pituitary tumor registry. Eur J Endocrinol 156(2):203–216
pubmed: 17287410
doi: 10.1530/eje.1.02326
pmcid: 17287410
Yap HY, Tashima CK, Blumenschein GR, Eckles N (1979) Diabetes insipidus and breast cancer. Arch Intern Med 139(9):1009–1011
pubmed: 475518
doi: 10.1001/archinte.1979.03630460043015
pmcid: 475518
Hagerstrand I, Schonebeck J (1969) Metastases to the pituitary gland. Acta Pathol Microbiol Scand 75(1):64–70
pubmed: 5796083
pmcid: 5796083
He W, Chen F, Dalm B, Kirby PA, Greenlee JD (2015) Metastatic involvement of the pituitary gland: a systematic review with pooled individual patient data analysis. Pituitary 18(1):159–168
pubmed: 24445565
doi: 10.1007/s11102-014-0552-2
pmcid: 24445565
Komninos J, Vlassopoulou V, Protopapa D, Korfias S, Kontogeorgos G, Sakas DE et al (2004) Tumors metastatic to the pituitary gland: case report and literature review. J Clin Endocrinol Metab 89(2):574–580
pubmed: 14764764
doi: 10.1210/jc.2003-030395
pmcid: 14764764
Morita A, Meyer FB, Laws ER Jr (1998) Symptomatic pituitary metastases. J Neurosurg 89(1):69–73
pubmed: 9647174
doi: 10.3171/jns.1998.89.1.0069
Ruelle A, Palladino M, Andrioli GC (1992) Pituitary metastases as presenting lesions of malignancy. J Neurosurg Sci 36(1):51–54
pubmed: 1323647
Cai H, Liu W, Feng T, Li Z, Liu Y (2019) Clinical presentation and pathologic characteristics of pituitary metastasis from breast carcinoma: cases and a systematic review of the literature. World Neurosurg
Marin F, Kovacs KT, Scheithauer BW, Young WF Jr (1992) The pituitary gland in patients with breast carcinoma: a histologic and immunocytochemical study of 125 cases. Mayo Clin Proc 67(10):949–956
pubmed: 1434855
doi: 10.1016/S0025-6196(12)60925-2
Barbaro D, Desogus N, Boni G (2013) Pituitary metastasis of thyroid cancer. Endocrine 43(3):485–493
pubmed: 23008095
doi: 10.1007/s12020-012-9806-9
Eichler AF, Loeffler JS (2007) Multidisciplinary management of brain metastases. Oncologist 12(7):884–898
pubmed: 17673619
doi: 10.1634/theoncologist.12-7-884
pmcid: 17673619
Hwang JM, Kim YH, Kim TM, Park SH (2013) Differential diagnosis and management of a pituitary mass with renal cell carcinoma. J Korean Neurosurg Soc 54(2):132–135
pubmed: 24175029
pmcid: 3809440
doi: 10.3340/jkns.2013.54.2.132
McCormick PC, Post KD, Kandji AD, Hays AP (1989) Metastatic carcinoma to the pituitary gland. Br J Neurosurg 3(1):71–79
pubmed: 2789715
doi: 10.3109/02688698909001028
pmcid: 2789715
Patchell RA (2003) The management of brain metastases. Cancer Treat Rev 29(6):533–540
pubmed: 14585263
doi: 10.1016/S0305-7372(03)00105-1
pmcid: 14585263
Houck WA, Olson KB, Horton J (1970) Clinical features of tumor metastasis to the pituitary. Cancer 26(3):656–659
pubmed: 5272295
doi: 10.1002/1097-0142(197009)26:3<656::AID-CNCR2820260325>3.0.CO;2-M
pmcid: 5272295
Sioutos P, Yen V, Arbit E (1996) Pituitary gland metastases. Ann Surg Oncol 3(1):94–99
pubmed: 8770309
doi: 10.1007/BF02409058
Habu M, Tokimura H, Hirano H, Yasuda S, Nagatomo Y, Iwai Y et al (2015) Pituitary metastases: current practice in Japan. J Neurosurg 123(4):998–1007
pubmed: 26186025
doi: 10.3171/2014.12.JNS14870
Lu JQ, Khalil M, Hu W, Sutherland GR, Clark AW (2009) Tumor-to-tumor metastasis: esophageal carcinoma metastatic to an intracranial paraganglioma. J Neurosurg 110(4):744–748
pubmed: 19072308
doi: 10.3171/2008.9.JNS08397
Bret P, Jouvet A, Madarassy G, Guyotat J, Trouillas J (2001) Visceral cancer metastasis to pituitary adenoma: report of two cases. Surg Neurol 55(5):284–290
pubmed: 11516470
doi: 10.1016/S0090-3019(01)00447-5
Fraggetta F, Galia A, Grasso G, D'Arrigo C, Cristaudo C, Giangaspero F (2000) Pulmonary adenocarcinoma metastatic to pituitary craniopharyngioma. J Clin Pathol 53(12):946–947
pubmed: 11265183
pmcid: 1731140
doi: 10.1136/jcp.53.12.946
Ramsay JA, Kovacs K, Scheithauer BW, Ezrin C, Weiss MH (1988) Metastatic carcinoma to pituitary adenomas: a report of two cases. Exp Clin Endocrinol 92(1):69–76
pubmed: 3229449
Lopes MBS (2017) The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol 134(4):521–535
pubmed: 28821944
doi: 10.1007/s00401-017-1769-8
Heshmati HM, Kujas M, Casanova S, Wollan PC, Racadot J, Van Effenterre R et al (1998) Prevalence of lymphocytic infiltrate in 1400 pituitary adenomas. Endocr J 45(3):357–361
pubmed: 9790270
doi: 10.1507/endocrj.45.357
Lafont C, Desarmenien MG, Cassou M, Molino F, Lecoq J, Hodson D et al (2010) Cellular in vivo imaging reveals coordinated regulation of pituitary microcirculation and GH cell network function. Proc Natl Acad Sci U S A 107(9):4465–4470
pubmed: 20160103
pmcid: 2840083
doi: 10.1073/pnas.0902599107
Megnis K, Mandrika I, Petrovska R, Stukens J, Rovite V, Balcere I et al (2016) Functional characteristics of multipotent mesenchymal stromal cells from pituitary adenomas. Stem Cells Int 2016:7103720
pubmed: 27340409
pmcid: 4909910
doi: 10.1155/2016/7103720
Mei Y, Bi WL, Greenwald NF, Du Z, Agar NY, Kaiser UB et al (2016) Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. Oncotarget 7(47):76565–76576
pubmed: 27655724
pmcid: 5363530
doi: 10.18632/oncotarget.12088
Wang PF, Wang TJ, Yang YK, Yao K, Li Z, Li YM et al (2018) The expression profile of PD-L1 and CD8(+) lymphocyte in pituitary adenomas indicating for immunotherapy. J Neuro-Oncol 139(1):89–95
doi: 10.1007/s11060-018-2844-2